Generic vs Brand GLP-1 in 2026 — Compounded vs Wegovy, Zepbound, Ozempic, Mounjaro

The one-sentence summary

There is no FDA-approved generic semaglutide or tirzepatide as of April 2026. Branded patents don’t expire in the US until 2031 (semaglutide) and 2036+ (tirzepatide). What exists is compoundedsemaglutide and tirzepatide, produced under specific FDA shortage-list exemptions by 503A and 503B pharmacies. That’s legally and clinically different from a generic. It’s cheaper; it’s also less regulated, less consistent, and may disappear as shortage designations are lifted.

The price reality across every access path

• Wegovy cash list: $1,349/mo. Almost nobody pays this.
• Zepbound cash list: $1,086/mo.
• Wegovy / Zepbound insured with savings card: $0–$50/mo copay for commercial coverage.
• LillyDirect Zepbound vials: $349–$499/mo (2.5 and 5 mg) as of 2026.
• NovoCare Wegovy vials: $499/mo all strengths.
• Compounded semaglutide: $199–$349/mo. Tirzepatide: $299–$499/mo.

The efficacy question

No head-to-head RCT compares branded and compounded. What we have: (a) manufacturer testing showing 50–80% label potency variance in compounded samples; (b) community-reported TBWL clustering 20–40% below trial mean at comparable nominal doses; (c) FDA FAERS reports of dosing errors (vials labeled in mg rather than units), contamination, injection site reactions. Average efficacy probably 20–40% below branded.

Where compounded still makes sense in 2026

1. Bridge during PA denial: $299 for 2–3 months while you appeal is reasonable.
2. Dose not sold by manufacturer at discount: Zepbound 7.5, 12.5 mg vials aren’t always available via LillyDirect.
3. Personalized formulations: B12-added or micro-dose sema (0.125–0.25 mg) for maintenance in patients who can’t tolerate labeled doses.
4. Patients without any insurance path: $299 cash may be the only realistic option vs stopping.

Where compounded doesn’t make sense

1. Commercial coverage at < $100/mo copay: arbitrage disappears.
2. History of pancreatitis, gallstones, MEN2, MTC family history: labeled product has risk mitigation; compounded varies.
3. SELECT CV indication driving therapy: FDA CV labeling attaches to Wegovy specifically.
4. Pregnancy / lactation / TTC within 2 months: contraindicated across the board.

How to evaluate a compounded pharmacy

• Ask 503A or 503B. 503B is materially higher oversight.
• Request COA on each lot — confirms potency, sterility, endotoxins.
• Prefer semaglutide sodium over semaglutide base.
• Verify state board of pharmacy license.
• Avoid “peptide research” suppliers selling “not for human use” product.